Menu
Recruiting NCT03238378

Salvage Brachytherapy and Hyperthermia for Recurrent H&N-tumours

No phase Interventional Locally Recurrent Head and Neck Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Brachytherapy, Hyperthermia.
Who it may be relevant to
Registry conditions: Locally Recurrent Head and Neck Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

SALVAGE BRACHYTHERAPY WITH INTERSTITIAL HYPERTHERMIA FOR LOCALLY RECURRENT HEAD & NECK CARCINOMA FOLLOWING PREVIOUSLY EXTERNAL BEAM RADIATION THERAPY: A PROSPECTIVE PHASE II STUDY

Overview

The aim of the present trial is to assess the prospective results of protocol-based interstitial pulsed-dose-rate (PDR) brachytherapy with interstitial hyperthermia (iHT) in a group of selected patients where salvage surgery with clear resection margins was not possible.

Interventions

  • Radiation Brachytherapy
    Brachytherapy d 1-5(6)
  • Other Hyperthermia
    Hyperthermia d 2 + 5

Primary outcome measures

  • Late side effects [Time frame: Effects are followed up to 5 years after therapy]
Secondary outcome measures (3)
  • Quality of life [Time frame: up to 5 years after therapy]
  • Rate of local recurrencies [Time frame: up to 5 years after therapy]
  • Overall survival [Time frame: up to 5 years after therapy]

Eligibility criteria

Inclusion criteria

  • Histologically confirmed recurrent carcinoma of the head and neck region
  • Stage rcT1-3
  • Tumor anatomy and location suitable for brachytherapy techniques.
  • cN0/pN0 or rpN+ \& R0 with <3 pos. LND \& without invasion of capsula.
  • M0
  • ECOG 0-2
  • Previous radiation therapy up to at least 50 Gy
  • Previous radiation therapy completed more than 6 months ago
  • Written study-specific informed consent

Exclusion criteria

  • cT4
  • rpN+ with >2 pos. LND or invasion of capsula
  • Pregnant or lactating women
  • Collagen vascular disease
  • The presence of congenital diseases with increased radiation sensitivity, for example Ataxia telangiectatica or similar
  • Psychiatric disorders

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Germany · 1 center
  • Dept. of Radiation Therapy, University Hospital Erlangen — Erlangen

Identifiers

NCT: NCT03238378 · HyBT-H&N

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗